All Stories

  1. Improving the efficacy of anti-SSEA4 antibody in pancreatic cancer immunotherapy with glyco-optimization and immune checkpoint blockade
  2. Cell-based glycoengineering for production of homogeneous and specific glycoform-enriched antibodies with improved effector functions
  3. Increased expression of SSEA-4 on TKI-resistant non–small cell lung cancer with EGFR-T790M mutation
  4. Low-sugar universal mRNA vaccine against coronavirus variants with deletion of glycosites in the S2 or stem of SARS-CoV-2 spike messenger RNA (mRNA)
  5. Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine
  6. Homogeneous antibody and CAR-T cells with improved effector functions targeting SSEA-4 glycan on pancreatic cancer
  7. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection
  8. Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes
  9. Methods for the preparation of mammalian oligosaccharides and glycoconjugates.